Acetylation Is Indispensable for p53 Activation  by Tang, Yi et al.
Acetylation Is Indispensable
for p53 Activation
Yi Tang,1 Wenhui Zhao,1 Yue Chen,3 Yingming Zhao,3 and Wei Gu1,2,*
1Institute for Cancer Genetics
2Department of Pathology and Cell Biology
College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA
3Department of Biochemistry, UT Southwestern Medical Center Dallas, TX 75390, USA
*Correspondence: wg8@columbia.edu
DOI 10.1016/j.cell.2008.03.025SUMMARY
The activation of the tumor suppressor p53 facilitates
the cellular response to genotoxic stress; however,
the p53 response can only be executed if its interac-
tion with its inhibitor Mdm2 is abolished. There have
been conflicting reports on the question of whether
p53 posttranslational modifications, such as phos-
phorylation or acetylation, are essential or only play
a subtle, fine-tuning role in the p53 response. Thus,
it remains unclear whether p53 modification is
absolutely required for its activation. We have now
identified all major acetylation sites of p53. Although
unacetylated p53 retains its ability to induce the p53-
Mdm2 feedback loop, loss of acetylation completely
abolishes p53-dependent growth arrest and apopto-
sis. Notably, acetylation of p53 abrogates Mdm2-
mediated repression by blocking the recruitment of
Mdm2 to p53-responsive promoters, which leads to
p53 activation independent of its phosphorylation
status. Our study identifies p53 acetylation as an in-
dispensable event that destabilizes the p53-Mdm2
interaction and enables the p53-mediated stress
response.
INTRODUCTION
The p53 tumor suppressor is a key component of a regulatory
circuit that monitors signaling pathways from diverse sources,
including DNA damage responses, abnormal oncogenic events,
and everyday normal cellular processes (Vogelstein et al., 2000;
Prives and Hall, 1999). p53 is tightly regulated, such that its pro-
tein product usually exists in a latent form, and at low levels, in
unstressed cells. However, the steady-state levels and tran-
scriptional activity of p53 increase dramatically in cells that sus-
tain various types of stress. While the precise mechanisms of
p53 activation are not fully understood, they are generally
thought to entail posttranslational modifications, such as ubiqui-
tination, phosphorylation, methylation, and acetylation, of the
p53 polypeptide (Brooks and Gu, 2003; Vousden and Lane,
2007).612 Cell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc.The functions of p53 are downregulated by the Mdm2 onco-
protein and a related protein Mdmx (also called Mdm4), at least
in part by ubiquitin-mediated proteolysis (Brooks and Gu, 2006;
Michael and Oren, 2003; Marine and Jochemsen, 2005). The
central role of Mdm2 in this process is best illustrated by studies
carried out in mice where inactivation of p53 was shown to com-
pletely rescue the embryonic lethality caused by loss of Mdm2
function (Jones et al., 1995; Montes de Oca Luna et al., 1995).
Nonetheless, the molecular mechanisms by which p53 activity
is controlled are complex. Although Mdm2, a really interesting
new gene (RING) oncoprotein, was once thought to be the sole
E3 ubiquitin ligase for p53, recent studies have shown that p53
is degraded in the tissues of Mdm2 null mice (Ringshausen
et al., 2006) and that other E3 ligases can also induce p53 ubiq-
uitination, such as ARF-BP1, COP1, and Pirh2 (Leng et al., 2003;
Dornan et al., 2004; Chen et al., 2005). In contrast, Mdmx does
not have intrinsic E3 ligase activity but Mdmx knockout mice
die despite having functional Mdm2, and this lethality is also res-
cued by inactivation of p53 (Marine and Jochemsen, 2005).
Thus, the role of Mdmx in repressing p53 function is as critical
as that of Mdm2. Moreover, accumulating evidence indicates
that degradation-independent mechanisms are crucial for both
Mdm2 and Mdmx in controlling p53 activities. Recent studies
suggest that Mdm2 mediates transcriptional repression by
forming a protein complex with p53 on the promoters of specific
p53-responsive genes (Minsky and Oren, 2004; Arva et al., 2005;
Ohkubo et al., 2006). Nevertheless, it remains unclear whether
similar mechanisms are also used forMdmx-mediated transcrip-
tion repression.
Histone acetyltransferases (HATs) represent an important layer
of p53 regulation, particularly in transcription (Brooks and Gu,
2003). The covalent linkage of an acetyl group to lysine, the enzy-
matic process of acetylation, was first discovered on histones,
and the significance of histone acetylation in transcriptional
regulation is well accepted (Jenuwein and Allis, 2001; Berger,
2007). However, histones are not the only proteins that can be
acetylated. p53 was the first nonhistone protein known to be
regulated by acetylation and deacetylation (Gu and Roeder,
1997; Luo et al., 2000). The acetylation levels of p53 are signifi-
cantly enhanced in response to stress and correlate well with
p53 activation and stabilization (Luo et al., 2000, 2001; Vaziri
et al., 2001; Ito et al., 2001; Barlev et al., 2001; Knights et al.,
2006; Li et al., 2007; Zhao et al., 2008; Kim et al., 2008). Recently,
an acetylation-deficient missense mutant (p53-6KR) was suc-
cessfully introduced into the endogenous p53 gene by a knockin
approach. Although p53-mediated transcriptional activation
upon DNA damage is partially impaired in the ESCs and thymo-
cytes of these mice, loss of p53 acetylation at its C terminus by
CBP/p300 is apparently not as essential as originally anticipated
(Feng et al., 2005; Krummel et al., 2005). Thus, it is possible that
other coactivators or additional acetylation sites of p53maycom-
pensate for the loss of p53 acetylation at its C terminus. Indeed,
we and others have shown that the Tip60/hMOF protein induces
p53 acetylation at lysine 120 (K120) within the DNA-binding do-
main, and that Tip60/hMOF, which shares no homology with
the CBP/p300 or PCAF acetyltransferases, is required for p53-
mediated transcriptional activation (Tang et al., 2006; Sykes
et al., 2006; Berns et al., 2004). Interestingly, K120 is a recurrent
site for p53 mutation in human cancer and Tip60/MOF-depen-
dent acetylation at K120 is important for p53-mediated apopto-
sis. Nevertheless, loss of K120 acetylation has no effect on
p53-mediated activation of p21, and the tumor-derived mutant
p53-K120R retains its ability to induce cell growth arrest (Tang
et al., 2006; Sykes et al., 2006).
Although numerous studies validate the crucial role of p21 in
p53-mediated tumor suppression (el-Deiry et al., 1993; Vogel-
stein et al., 2000), the molecular mechanism by which p53 in-
duces p21 expression is not well understood. Here we have
identified K164 as a new site for in vivo acetylation of p53 by
CBP/p300 and evaluated its function in these processes. Al-
though acetylation defects at each individual site (K164, K120,
and C terminus) can be compensated by the modification of
other sites, loss of acetylation at all these major sites completely
abolishes its ability to activate p21 and suppress cell growth.
Moreover, acetylation blocks the interaction of p53 with its cog-
nate repressors (Mdm2 and Mdmx) on DNA, and this event di-
rectly results in p53 activation regardless of its phosphorylation
status. Notably, the transcriptional functions of unacetylated
p53 can be restored by inactivation of Mdm2 and Mdmx. These
data have significant implications regarding an essential role of
acetylation in p53 regulation.
RESULTS
K164 Is a New Acetylation Site Catalyzed by CBP/p300
To further elucidate acetylation-mediated effects on p53, we
used mass spectrometric (MS/MS) analysis to identify all modi-
fication sites induced by CBP/p300. To increase the yield of
acetylated forms of p53, we treated the cells with deacetylase in-
hibitors such as trichostatin A (TSA) and nicotinamide for 6 hr be-
fore isolating acetylated p53 from these cells. Consistent with
previous studies, mass spectrometric analysis revealed modifi-
cation of the known acetylation sites, including the six C-terminal
lysine residues: K370, K372, K373, K381, K382, and K386. Inter-
estingly, however, a p53 peptide with amolecular weight consis-
tent with acetylation of lysine 164 (K164) was also identified
(Figures 1A and 1B), suggesting the existence of a novel
modification site within the DNA-binding core domain of p53.
K164, which is located in the L2 loop of the DNA-binding core
domain of p53, is conserved in all the species known to encode
p53— including human, mouse, Xenopus, and zebrafish—aswell as in p53-related proteins p63 and p73 (Figure 1C). More-
over, tumor-associated mutations of K164 have been observed
in several different types of human tumors (http://p53.free.fr).
To confirm acetylation of p53 proteins at K164, we developed
an antiserum that specifically recognizes K164-acetylated p53
(AcK164-p53) (see Experimental Procedures and Figure S1).
To avoid crossreactivity with other acetylation sites by this anti-
body, we compared its reactivity to two substrate proteins: the
p53-7KR mutant, in which the seven known acetylated sites
(K120 and the six C-terminal lysine residues) were all substituted
with arginine; and the p53-8KR mutant, in which the seven
known sites and K164 are all substituted with arginine. Upon
in vitro acetylation with recombinant CBP and p300 proteins,
the p53-7KR but not the p53-8KR polypeptide was recognized
by the AcK164-p53 antibody (Figure 1D). To examine acetylation
of endogenous p53, we used the acetylation-specific antibody to
measure the levels of K164-acetylated p53 in untreated and
DNA-damaged cells. As shown in Figure 1E, upon stabilization
of p53 proteins, the steady-state levels of K164 acetylation
were also enhanced. These data indicate that K164 is acetylated
both in vitro and in vivo.
SimultaneousMutation at All theMajor Acetylation Sites
Completely Abolishes p53-Mediated Activation of p21
We and others recently showed that K120 acetylation is crucial
for p53-mediated apoptosis but has no effect on the induction
of p21 and cell growth arrest (Tang et al., 2006; Sykes et al.,
2006). To elucidate the effect of K164 acetylation on p53-depen-
dent transcriptional activation, we examined whether loss of
K164 acetylation influences p53-mediated p21 activation. As
shown in Figure 2B, expression of wild-type p53 led to strong in-
duction of p21, and a slight reduction but comparable degree of
p21 induction was also obtained upon expression of K164R mu-
tant p53. Moreover, consistent with previous studies (Tang et al.,
2006; Sykes et al., 2006), p53 mutants that lack C-terminal ly-
sines or K120, but retain K164, readily activate p21 under these
conditions (Figures 2B and S2). Strikingly, loss of acetylation only
at all eight sites (p53-8KR) completely abolished p21 induction
(Figures 2A, 2B, and 2C). Thus, although individual mutations
at each acetylation site have no significant effect on its ability
to induce p21, loss of acetylation at all sites (p53-8KR) greatly
impairs p53-dependent transcription.
The Acetylation-Defective p53Mutant Retains Its Ability
to Act as a DNA-Binding Transcription Factor that
Induces the p53-Mdm2 Feedback Loop
Lysine-to-arginine mutants are commonly used to mimic unace-
tylated forms of histone in transcriptional regulation (Jenuwein
and Allis, 2001). Nevertheless, two of the p53 acetylation sites
(K120 and K164) reside within the DNA-binding domain, and it
is known that many tumor-associated mutations in this domain
can inactivate p53 function by ablating its DNA-binding activity
(Vogelstein et al., 2000). Thus, we used an electrophoretic mobil-
ity shift assay (EMSA) to ascertain whether loss of these acetyla-
tion sites affects sequence-specific DNA binding by p53. As
shown in Figure 2D, p53/DNA complexes were obtained by incu-
bation of highly purified, recombinant full-length human wild-
type p53 with a radiolabeled probe containing the p53-bindingCell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc. 613
Figure 1. Identification of K164 within the Human p53 DNA-Binding Domain as a Novel Acetylation Site by p300/CBP
(A) Schematic representation of the human p53 protein with known acetylation sites indicated, including K120, K370, K372, K373, K381, K382, and K386. In this
study, K164 was identified to be acetylated by p300/CBP.
(B) Mass spectrometry analysis of the p53-derived peptides containing acetylated K164 (AcK164). The protein was prepared as described in the Experimental
Procedures.
(C) Alignment of the K164 flanking region of the human p53 protein with those of p53 from other species and of human p63 and p73. The conserved lysine residue
is marked in bold; h: human; m: mouse; c: chicken; x: Xenopus; and z: zebrafish.614 Cell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc.
site from the p21 promoter. Significantly, the DNA-binding activ-
ity of the wild-type and 8KR mutant forms of p53 were indistin-
guishable, indicating that the eight lysine-to-arginine substitu-
tions, including K120R and K164R, do not abolish the DNA
binding. Moreover, both forms of p53 also bound equally to
the transcriptional coactivators/acetylases CBP and Tip60 (Fig-
ures S3A and S3B), as well as with Mdm2 andMdmx (Figure S4).
Consistent with its ability to bind DNA and to associate with its
transcriptional coactivators, p53-8KR retained its full capacity to
transactivate Mdm2 expression (Figure 2B). We also tested
whether Mdm2 can induce degradation of p53-8KR in human
cells. As shown in Figure 2E, although some effects were
expected given that the p53-8KR protein lacks the major C-ter-
minal ubiquitination sites, p53-8KR was degraded by Mdm2 in
human cells. Taken together, these results indicate that the
acetylation-defective mutant p53-8KR retains its abilities to act
as a DNA-binding transcriptional factor that induces the
p53-Mdm2 feedback loop.
Acetylation Is Essential for p53-Mediated Cell Growth
Arrest and Apoptosis
To evaluate the role of p53 acetylation under physiological con-
ditions, we established inducible cell lines expressing tetracy-
cline-regulated wild-type p53 or acetylation-defective 8KR mu-
tant p53. These cells express relatively low levels of p53 upon
withdrawal of tetracycline (Zupnick and Prives, 2006). As shown
in Figure 3A, the levels of p53 inducedwere very close to those of
endogenous p53 in HCT116 cells upon DNA damage treatment.
Moreover, after removing tetracycline from the medium, the
levels of both wild-type p53 and p53-8KR were increased to a
similar degree. As expected, wild-type p53, but not p53-8KR,
was acetylated at all sites examined by acetylation-specific an-
tibodies (Figure 3B). In addition, both wild-type p53 and p53-
8KR were phosphorylated at similar levels (lane 4 versus 2,
Figure 3B), indicating that the acetylation mutations do not affect
on the phosphorylation status of p53.
To examine the transcriptional activity of p53 at low levels of
expression, we monitored p21 expression during the course of
a 4-day Tet-off induction. Although Mdm2 and p21 were both
gradually activated in wild-type p53 cells, Mdm2 (but not p21)
was induced in p53-8KR cell lines (Figure 3C). We also com-
pared the effects of wild-type p53 and p53-8KR on cell growth
by monitoring BrdU incorporation. Less than 5% BrdU-positive
cells were detected in the Tet-off-p53 cells at 4 days after p53 in-
duction. In contrast, more than 50% BrdU-positive cells were
observed in the p53-8KR Tet-off cells (Figures 3D and 3E). More-
over, consistent with previous studies (Tang et al., 2006; Sykes
et al., 2006), loss of acetylation abrogates p53-mediated activa-
tion of proapoptotic targets such as BAX, PUMA, and Pig3(Figure 3C), and no apoptosis was induced by the acetylation
mutant p53-8KR (Figure S5). Together, these data suggest that
modification of these sites is required for both growth arrest
and apoptosis induced by p53.
Acetylation of p53 Blocks the Recruitment
of Mdm2 to the p21 Promoter
To elucidate the mechanism of p53 acetylation in p21 activation
in cells, we performed chromatin immunoprecipitation (ChIP)
assays with cells expressing either wild-type or acetylation-
defective p53 proteins. Thus, the cells were transfected with
expression vectors encoding either wild-type p53 or p53-8KR,
together with expression vectors for Mdm2 and the known p53
acetylases (CBP and Tip60). At 36 hr after transfection, the cells
were fixed with 1% formaldehyde for ChIP analysis. Immunopre-
cipitation with the p53-specific antibody revealed that both wild-
type p53 and p53-8KR can be recruited to the p21 promoter
(Figure 4A). Moreover, in the presence of Mdm2 expression,
the levels of recruitment were decreased for both wild-type
p53 and p53-8KR (Figure 4A), which reflects degradation of
p53 induced by Mdm2 (Figure 4B). Since several recent studies
showed that the transcriptional repression activity of Mdm2 re-
quires p53-mediated recruitment of Mdm2 to the p21 promoter
(Minsky and Oren, 2004; Ohkubo et al., 2006; Arva et al.,
2005), we examined whether Mdm2 recruitment is modulated
by p53 acetylation. As expected, immunoprecipitation with the
Mdm2-specific antibody revealed that both wild-type p53 and
p53-8KR can form protein complexes with Mdm2 on the p21
promoter in human cells (lanes 3 and 6, Figure 4A). Interestingly,
coexpression of the CBP and Tip60 acetylases with wild-type
p53, which led to increasing levels of p53 acetylation (lane 4,
Figure 4B), severely ablated Mdm2 recruitment to the p21 pro-
moter (lane 4, Figure 4A); conversely, however, Mdm2 recruit-
ment was unaffected by coexpression of the acetylases with
acetylation-defective p53 (lane 7, Figure 5A). Thus, these data
suggest that p53 acetylation represses recruitment of Mdm2 to
the p21 promoter.
Acetylation of p53 Inhibits Recruitment
of Mdm2 and Mdmx to the p21 Promoter
in a Ubiquitination-Independent Manner
Numerous studies demonstrate that Mdm2 employs both ubiq-
uitination-dependent and ubiquitination-independent mecha-
nisms to control p53 activity in vivo. In contrast, since Mdmx
cannot directly catalyze p53 ubiquitination, it is thought to re-
press p53 function in a degradation-independent manner. To ex-
amine ubiquitination-independent p53 regulation by Mdm2 and
Mdmx, we tested the effects of p53 acetylation on promoter
recruitment of both Mdmx and Mdm2-C464A, an ubiquitin(D) In vitro acetylation of p53 by p300/CBP. The Flag-p53-K120R/6KR (lanes 2, 4, and 6) or Flag-p53-K120R/K164/6KR (lanes 1, 3, and 5) recombinant protein
was incubated alone (lanes 1 and 2), with p300 (lanes 3 and 4), or with CBP (lanes 5 and 6). The reaction products were resolved by SDS-PAGE and analyzed by
western blot using the site-specific polyclonal antibody against acetylated K164 (anti-AcK164-p53) (top panel). The levels of the p53 recombinant protein sub-
strates are shown in the bottom panel by Ponceau red staining.
(E) Acetylation of the endogenous p53 protein at K164. HCT116 cells were treated with 20 mM etoposide (0, 4, and 6 hr). The endogenous p53 proteins were
immunoprecipitated by the anti-p53 (1801) antibody and assayed for acetylation by western blot using the anti-AcK164-p53 antibody (top panel). The levels
of p53 in the cell extracts are shown in the middle panel.Cell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc. 615
Figure 2. Functional Characterization of Acetylation-Defective p53 Mutants
(A) Scheme of the human p53 lysine-to-arginine mutants used in this study.
(B) Induction of p21 andMdm2 by p53 lysine-to-arginine mutants. H1299 cells were transfected with increasing amount of plasmid DNA expressing different p53
mutants. The total cell extracts were subjected to western blot for p53, p21, and Mdm2, and GFP was used as a transfection control.
(C) As in (B), two additional p53 lysine-to-arginine mutants were examined.
(D) In vitro DNA-binding activities of p53 and p53-8KR. Gel shift assay was performed using a fragment containing a p53-binding site from the p21 promoter, as
described in the Experimental Procedures.
(E) Degradation of the p53 and p53-8KR proteins by Mdm2. H1299 cells were cotransfected with CMV-p53 expressing either p53 or p53-8KR and an increased
amount of CMV-Mdm2. The cellular levels of p53 were determined by western blot using anti-p53 antibody (DO-1).616 Cell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc.
ligase-defective mutant of Mdm2. Thus, the cells were trans-
fected with expression vectors encoding wild-type p53 or p53-
8KR, together with Mdmx and Mdm2-C464A in the presence
or absence of acetylases (CBP, Tip60). As shown in Figure 4C,
both Mdmx and Mdm2-C464A can be recruited to the p21 pro-
moter. Again, these recruitments were abrogated in cells ex-
pressing wild-type p53, but not p53-8KR, upon coexpression
of CBP and Tip60 (lanes 4 and 7, Figure 4C). These data indicate
that acetylation of p53 inhibits recruitment of Mdm2 and Mdmx
to the p21 promoter in an ubiquitination-independent manner.
We then examined whether similar acetylation-mediated ef-
fects influence transactivation of other p53 target promoters.
Previous studies indicated that Mdm2 can also be recruited to
the Pig3 promoter (Ohkubo et al., 2006). Similar to p21 expres-
sion, we observed Pig3 induction by wild-type p53 but not by
the acetylation-defective p53-8KR (Figure 3C). ChIP analysis
revealed that Mdm2 and Mdmx were recruited to the Pig3
promoter to a comparable degree by both wild-type p53 and
p53-8KR. In contrast, the recruitment of Mdm2 and Mdmx by
wild-type p53, but not p53-8KR, was severely inhibited by coex-
pression of CBP and Tip60 (Pig3 promoter, Figure 4C).
Finally, since acetylation-defective p53-8KR retains the ability
to induce Mdm2 (Figure 2B), we tested the effects of p53 acety-
lation on recruitment of Mdm2 and Mdmx to the Mdm2 pro-
moter. As expected, ChIP analysis demonstrates that both
wild-type p53 and p53-8KR can be recruited to the Mdm2 pro-
moter (Mdm2 promoter, Figure 4C). Consistent with our previous
studies (Tang et al., 2006), Tip60 was recruited to the p21 pro-
moter—but not Mdm2 promoter—in the presence of wild-type
p53 or p53-8KR, whereas CBP was recruited to both promoters
in the presence of wild-type p53 or p53-8KR. Interestingly, how-
ever, the recruitment of bothMdm2 andMdmx to theMdm2 pro-
moter was extremely weak, and this modest level of recruitment
was unaffected by coexpression of Tip60 and CBP (Mdm2 pro-
moter in Figures 4C and S9). These results suggest that the
recruitment of Mdm2 or Mdmx by p53 to the Mdm2 promoter
is not significantly affected by the acetylation status of p53. To
extend these findings, we identified Pirh2 as another p53 target
(Leng et al., 2003), whose induction by p53 is independent of the
acetylation status (Figure S10). Taken together, these data dem-
onstrate that loss of acetylation does not affect p53’s ability to
act as a transcription factor but significantly abrogates acetyla-
tion-induced inhibition of Mdm2 and Mdmx recruitment in a
promoter-specific manner.
Acetylation of p53 Destabilizes the p53-Mdm2
Complex Formation
To provide direct evidence for the above hypothesis, we used an
in vitro system to test whether acetylation blocks the interactions
of DNA-bound p53 with Mdm2 and Mdmx. To this end, p53,
p53-8KR,Mdm2, andMdmxwere each purified to near homoge-
neity (Figure S6A). Acetylated p53 was prepared in the presence
of Tip60 and CBP essentially as previously described (Luo et al.,
2004), and the acetylation status of p53 was verified with acety-
lation-specific antibodies (Figure 5A). An EMSAwas then used to
examine whether Mdm2 can form a protein complex with DNA-
bound p53. As shown in Figure 5B, recombinant p53 readily
forms a p53-DNA complex with a 159 base pair DNA fragmentderived from the p21 promoter, as previously reported (Luo
et al., 2004). In the presence of Mdm2, a more slowly migrating
complex was formed (lane 5, Figure 5B), and this complex was
either supershifted by the p53-specific antibody or blocked by
the Mdm2-specific antibody (lanes 6 and 7, Figure 5B), suggest-
ing the formation of an Mdm2-p53-DNA ternary complex. To ex-
amine the effect of p53 acetylation on Mdm2 recruitment, we
compared complex formation by unacetylated and acetylated
p53 polypeptides. As expected, when increasing amounts of
Mdm2 were introduced in the reactions, unacetylated p53
formed the slowly migrating Mdm2-p53-DNA ternary complex
(lanes 8–10, Figure 5C). The same complex was formed with
the p53-8KR protein (lane 5, Figure 5C), implying that p53-8KR
behaves like unacetylated p53 with respect to Mdm2 recruit-
ment. In contrast, although acetylated p53-bound DNA more
effectively than unacetylated p53 (lane 11, Figure 5C), as previ-
ously reported (Luo et al., 2004), Mdm2 was unable to form the
Mdm2-p53-DNA ternary complex with acetylated p53 (lanes
12–14, Figure 5C). Similar results were also obtained with the
inhibitory effect of p53 acetylation on formation of an Mdmx-
p53-DNA ternary complex (Figure S11).
Finally, to extend these observations, we tested whether acet-
ylation affects the p53-Mdm2 interaction in the absence of DNA.
Although it is well accepted that the N terminus of p53 is crucial
for interactions with Mdm2, our data indicate that p53 acetyla-
tion outside the N terminus modulates the p53/Mdm2 interac-
tion. Thus, we first examined whether other regions of p53 are
also involved in this interaction. To this end, the recombinant
p53 fusion proteins containing different regions (N terminus,
aa 1–73; core domain, aa 100–290; C terminus, aa 290–393)
wereexpressedandpurified to near homogeneity for in vitrobind-
ing assays (Figure S6B). As expected, 35S-labeled in vitro-trans-
lated Mdm2 bound the recombinant protein GST-p53 (aa 1–73)
(lane 2, Figure 5D) but not GST (lane 5, Figure 5D). Surprisingly,
both the core domain and the C terminus of p53 showed similar
binding affinities for Mdm2 (lanes 3 and 4, Figure 5D), indicating
that these two regions are also involved in the stable interaction
between p53 andMdm2.More importantly, to examine the effect
of acetylation in this interaction, we performed similar GST-pull-
down assays with either purified unacetylated p53 or acetylated
p53 proteins. As shown in Figure 5E, western blot analysis re-
vealed that unacetylated forms bound strongly to both Mdm2
andMdmx; however, acetylation of p53 strongly abrogated these
interactions. Taken together, these data indicate that there are
multiple regions of p53 involved in its interaction with Mdm2 or
Mdmx and that acetylation of p53 significantly destabilizes the
complex formation with Mdm2 or Mdmx.
p53 Acetylation Is Essential for Inhibiting the p53-Mdm2
Complex Formation During the DNA Damage Response
Both phosphorylation and acetylation of p53 are commonly in-
duced uponmany types of stress (Brooks andGu, 2003). In order
to demonstrate the essential role of p53 acetylation under phys-
iological settings, we had to test whether acetylation of p53 is
crucial for abrogating Mdm2-mediated repression during the
stress response independent of p53 phosphorylation status. In-
terestingly, it was reported that p53 can be activated normally
without inducing its phosphorylation at the N terminus uponCell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc. 617
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certain types of DNA damage such as actinomycin D treatment
(Ashcroft et al., 1999, 2000; Ito et al., 2001). To dissect the role
of p53 acetylation alone during the DNA damage response, we
examined the effect of p53 acetylation in human osteosarcoma
U20S cells in the presence of actinomycin D treatment. As
shown in Figure 6A, upon the treatment, p53 was stabilized
and p53-mediated activation of p21 was significantly induced.
Indeed, despite a robust elevation of p53 acetylation levels, no
significant increase of its phosphorylation levels could be de-
tected at any time point (Figure 6A). To evaluate the role of p53
acetylation in modulating the p53-Mdm2 complex on chromatin,
we performed chromatin immunoprecipitation (ChIP) assays
with these cells. As expected, immunoprecipitation with the
p53 antibody showed that an increasing amount of p53 associ-
ated with the p21 promoter (Figure 6B); conversely, although
the levels of Mdm2 were elevated (Figure 6A), the recruitment
of Mdm2 to the p21 promoter by p53 was severely inhibited
when p53 was acetylated (Figure 6B).
Moreover, to further elucidate the requirement of acetylation
during this event, we performed the same assay by using the
acetylation-defective mutant (p53-8KR). Thus, p53 null H1299
cells were first infected with either Ad-p53 or Ad-p53-8KR and
were then treated with actinomycin D for further analysis. As
shown in Figure 6C, acetylation of wild-type p53 at all different
sites was significantly induced whereas no obvious enhance-
ment of p53 phosphorylation was detected after the treatment
with actinomycin D. Using ChIP, we found that Mdm2 recruit-
ment at the p21 promoter was strongly repressed upon actino-
mycin D treatment in a manner that correlated with the acetyla-
tion levels of wild-type p53 (lane 2 versus lane 1, Figure 6D). In
contrast, no obvious difference in Mdm2 recruitment at this
promoter was detected by the acetylation defective mutant
p53-8KR (lane 4 versus lane 3, Figure 6D). Taken together, these
data demonstrate that p53 acetylation is essential for inhibiting
the p53-Mdm2 complex formation on the p21 promoter during
DNA damage responses.
The Functional Defects of Unacetylated p53 Can Be
Rescued by Removing Mdm2 and Mdmx from Cells
The above results suggest that unacetylated p53 is more vul-
nerable to the repressive effects of Mdm2 and Mdmx and that
acetylation can activate p53 function by blocking Mdm2/
Mdmx-mediated downregulation. To elucidate the physiological
significance of this mechanism, we tested whether the transac-
tivation potential of acetylation-defective p53 can be restored by
RNAi-mediated knockdown of Mdm2 and Mdmx. To this end,
the Tet-off p53-8KR cells were transfected with control siRNAor with siRNAs specific for Mdm2 or Mdmx. Two days after
transfection, p53 expression was induced by removing tetracy-
cline from the medium. As expected, p21 induction was not ob-
served in p53-8KR cells transfected with control RNAi; however,
significant levels of p21 and Pig3 were induced in cells subject to
siRNA-mediated depletion of Mdm2, Mdmx, or the combination
of both Mdm2 and Mdmx (lanes 8–10, Figure 7A). To avoid off-
target effects by RNAi-mediated knockdown, we also obtained
the same results with different RNAi oligos against the mRNA
of either Mdm2 orMdmx (data not shown). As a negative control,
we performed the similar experiments with two additional p53
mutants, which are unable to interact with Mdm2 (Figure S12),
to support the same conclusion.
Next, we examined the effects of Mdm2 and Mdmx depletion
on the growth suppression activity of p53 and p53-8KR. Both the
wild-type p53 and p53-8KR cell lines were cultured in Tet-free
medium to induce p53 expression, and cells were stained with
crystal violet 5 days after tetracycline withdrawal. As expected,
induction of wild-type p53—but not p53-8KR—strongly sup-
pressed tumor cell growth (upper panel in Figure 7B). Signifi-
cantly, the ability of acetylation-defective p53-8KR to suppress
cell growth was partially rescued by siRNA-depletion of Mdm2
and Mdmx (lower panel in Figure 7B). Taken together, these
data indicate that the acetylation defective mutant of p53 does
not lose its activity permanently and that its mediated activation
of p21 and cell growth repression can be at least in part restored
by inactivation of Mdm2 and Mdmx in human cells.
DISCUSSION
p53 is regulated by a variety of posttranslational modifications,
including phosphorylation, acetylation, methylation, ubiquitina-
tion, sumoylation ,and neddylation (Vousden and Lane, 2007;
Brooks and Gu, 2006; Berger, 2007). While ubiquitin-mediated
proteasomal degradation is well accepted as a key mechanism
for controlling p53 levels, it remains controversial how p53 is ac-
tivated. Indeed, numerous studies indicate potential roles for
phosphorylation and acetylation in p53 regulation; nevertheless,
it was under debate whether protein modification is absolutely
required for p53 activation. Following our early findings of C ter-
minus p53 acetylation, we and others recently showed that p53
is also acetylated by Tip60/hMOF at residue K120 within the
DNA-binding domain (Tang et al., 2006; Sykes et al., 2006).
K120 acetylation is crucial for p53-mediated apoptosis but has
no obvious effect on p21 expression, an essential target of
p53-mediated growth arrest (el-Deiry et al., 1993). Although the
molecular mechanism of p21 transactivation is not wellFigure 3. Lack of Acetylation at Its DNA-Binding Domain and C Terminus Abolishes p53 Ability to Induce Cell Growth Arrest
(A) Expression of the human p53 protein at physiological levels in Tet-off-p53 H1299 cells. The total cell extracts from Tet-off-p53 cells (before and after induction)
and HCT116 cells (treated without and with etoposide) were assayed by western blot using the antibodies against p53 (DO-1) and actin.
(B) Acetylation of p53 in Tet-off-p53 cells. The Flag-p53 proteins enriched from Tet-off-p53 and Tet-off-p53-8KR cells byM2 immunoprecipitation were subjected
to western blot analysis using acetylation- and phosphorylation-specific antibodies, as indicated, and anti-p53 (1801) to determine the levels of total p53.
(C) Tet-off-p53 and Tet-off-p53-8KR cells were induced for 0, 1, 2, 3, and 4 days. The total cell extracts were analyzed by western blot using antibodies against
p53 (DO-1), Mdm2, Bax, Puma, Pig3, p21, and actin.
(D) Four days after induction, Tet-off-p53 and Tet-off-p53-8KR cells were treated with 10 mM Brdu for 1 hr and immunostained with the anti-BrdU antibody. The
nuclei are in blue (DAPI), and Brdu-positive nuclei are shown in red.
(E) Tet-off-p53 and Tet-off-p53-8KR cells were induced as in (C), and incorporation of BrdU was assayed as in (D).Cell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc. 619
understood, the p21 gene is induced by p53 in almost all cell
types by a variety of stresses, suggesting that multiple pathways
can promote its activation. Consistent with this notion, while loss
of acetylation at each individual site can be compensated by the
modification of other sites, loss of acetylation at all sites com-
pletely abolishes p53-mediated transactivation of p21. Thus,
Figure 4. Acetylation of p53 Abrogates the Promoter-Specific Recruitment of Mdm2 and Mdmx
(A) H1299 cells transfected by various plasmids, as indicated, were treated with 1% formaldehyde for 10min and processed for ChIP analysis. The occupancy of
p53, Mdm2, CBP, and Tip60 of the p21 promoter was detected by PCR.
(B) Acetylation of p53 in the presence of CBP and Tip60. H1299 cells were transfected as in (A), and Flag-p53 immunoprecipitated withM2 beads was assayed for
acetylation at specific sites by western blot. Expression of Mdm2, CBP, and Tip60 was detected in the total cell extracts.
(C) H1299 cells transfected by the indicated plasmids were treated with 1% formaldehyde for 10 min and processed for ChIP analysis as in (A). The occupancy of
p53, Mdm2, Mdmx, CBP, and Tip60 of the p21, Pig3, and Mdm2 promoters was detected by PCR-agarose gel electrophoresis. The relative levels of recruitment
of Mdm2 and Mdmx were further quantitated by real-time PCR as shown in Figures S7, S8, and S9.620 Cell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc.
although expression of p21 likely is redundantly regulated by p53
through modifications of multiple modification sites, our data
demonstrate that acetylation is an indispensable event for
p53-mediated activation of p21 and subsequent growth arrest.
Earlier studies from us and others showed that acetylation
modulates p53 function through multiple mechanisms, including
DNA binding, stability control, and coactivator recruitment
(Brooks and Gu, 2003). Although we indeed observed these
acetylation-mediated effects contribute, in part, to overall p53
activation (Figures 4A, 4B, and 5C), the dramatic loss of p53
functions in both growth arrest and apoptosis (but not in
Mdm2 induction) with acetylation-defective p53 suggests the in-
volvement of additional mechanisms. Recent studies have
established crucial roles for both Mdm2 andMdmx in controlling
p53 activity in vivo (Michael and Oren, 2003; Marine and
Jochemsen, 2005). Since Mdm2 can induce p53 degradation
by ubiquitin-mediated proteolysis and downregulate p53 func-
tion by repressing p53-mediated transactivation, both ubiquiti-
nation-dependent and ubiquitination-independent mechanisms
have been proposed for Mdm2-mediated regulation of p53. In
contrast, the molecular mechanism by which Mdmx, which is
enzymatically inactive as an E3 ubiquitin ligase, downregulates
p53 is unclear. Here we show that Mdmx, in a manner similar
to Mdm2, can be recruited to p53 target promoters to serve as
a transcriptional repressor. Importantly, acetylation prevents
downregulation of p53 function by blocking the recruitment of
both Mdm2 and Mdmx to p53 responsive promoters.
Inhibition of the p53-Mdm2 interaction is well accepted as
a central event for p53 activation during the stress response.
Several earlier reports indicated that phosphorylation of the N
terminus is essential for p53 activation as the phosphorylation
sites lie in or close to the MDM2 binding site on p53; however,
a number of other studies have recently shown that p53 can
be activated regardless of its phosphorylation status (Ashcroft
et al., 1999, 2000; Dumaz and Meek, 1999; Blattner et al.,
1999; Wu et al., 2002; Thompson et al., 2004; Prives and Hall.,
1999). Thus, it remains a major issue regarding how p53 is acti-
vated without inducing its phosphorylation. Our study demon-
strates that acetylation of p53 is sufficient for abrogating
Mdm2-mediated repression during the stress response in the
absence of phosphorylation. The antirepression mechanism de-
scribed here explains why the function of unacetylated p53 can
be restored in human cells by the loss of the p53 repressors
(Mdm2 and Mdmx). Other lines of evidence also support this
mechanism. For example, the unexpected activity of unacety-
lated p53 in reconstituted in vitro transcription reactions with
purified components can now be explained by the absence of
Mdm2 and Mdmx in this system (An et al., 2004; Espinosa and
Emerson, 2001). Moreover, the mechanism presented here is
also consistent with recent studies showing that p53 is sponta-
neously activated in Mdm2 null mice (Ringshausen et al., 2006).
Notably, in addition to the N-terminal domain, the DNA-bind-
ing domain of p53 was recently identified as a second binding
site for Mdm2 interaction (Yu et al., 2006; Kulikov et al., 2006).
Surprisingly, we found that all three major domains of p53 (N ter-
minus, core region, and C terminus) show similar binding affini-
ties for Mdm2, which raised the possibility that multiple contact-
ing sites are involved in the stable interaction between p53 andMdm2. The relationship among phosphorylation, acetylation,
and other modifications in p53 regulation warrants further inves-
tigations. It is very likely that phosphorylation (e.g., the N termi-
nus) and acetylation of p53 have synergistic effects on inhibiting
the p53-Mdm2 interaction, the most crucial step for p53 activa-
tion. Indeed, agents that block this interaction, including Nutlin-
3, a small molecule antagonist of Mdm2, attract huge interests
for their potentials in cancer therapy (Vassilev, 2007). However,
blocking the p53-Mdm2 interaction is apparently not sufficient
to turn on all p53-responsive promoters. Recent studies showed
that the treatment of Nutlin-3 strongly induces p53-dependent
growth arrest in cancer cells but has a much-reduced ability to
activate proapoptotic targets of p53 (Tovar et al., 2006).
Thus, p53 acetylation may have additional functions besides
destabilizing the p53-Mdm2 interaction. Since two key acetyla-
tion sites (K120 and K164), in addition to a cluster of acetylation
sites at the C terminus reside in the DNA-binding core domain of
p53, it will be interesting to know whether acetylation of these
sites changes the conformation of p53 in a manner that attracts
other promoter-specific regulators. For example, there is accu-
mulating evidence showing that the core domain and the C ter-
minus may be the docking sites for several important p53 coac-
tivators such as ASPPs, 53BP1, Tip60/hMOF, hCAS/CSE1L, and
HZF, which are all critically involved in the induction of different
targets by p53 (Sullivan and Lu, 2007; Das et al., 2007; Tanaka
et al., 2007; Li et al., 2007; Tang et al., 2006; Sykes et al.,
2006; Joo et al., 2002). The interactions between p53 and these
factors may be modulated by acetylation. Moreover, the differ-
ential effect of p53 acetylation on Mdm2/Mdmx recruitment to
p53 target promoters needs further elucidation. We failed to de-
tect a significant effect on the Mdm2 promoter by p53 acetyla-
tion, which is consistent with normal Mdm2 induction by the
acetylation-defective p53 mutant. Thus, the consequences of
p53 acetylation are promoter specific and different architectures
of the p53-DNA complexes at various p53 target sequencesmay
also contribute to such specificities.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
H1299, U2OS, and 293cells were maintained in DMEM medium and HCT116
cells in McCoy’s 5A medium. All media were supplemented with 10% fetal
bovine serum. The inducible cell lines (Tet-off-p53 and Tet-off-p53-8KR)
were established by transfection of H1299 cells with the plasmid DNA (pTRE2-
hyg-Flag-p53 or pTRE2hyg-Flag-p53-8KR) and selection in DMEM medium
supplemented with 5 mg/ml doxycycline (Sigma), 0.2 mg/ml G418 (EMD Bio-
sciences), and 0.4 mg/ml hygromycin B (Roche) for 3 weeks. Transfections
with plasmid DNA were performed using the calcium phosphate method and
siRNA transfections by Lipofectamine2000 (Invitrogen) according to the man-
ufacturer’s protocol.
DNA Binding
The highly purified proteins used in EMSA include Flag-p53, Flag-p53-8KR,
acetylated Flag-p53, GST-Mdm2, and GST-Mdmx. Flag-p53 and Flag-p53-
8KR were purified from the transfected 293 cells, GST-Mdm2, and GST-
Mdmx from bacteria, and the acetylated Flag-p53 from H1299 cells cotrans-
fected with CMV-Flag-p53, CMV-Tip60, and CMV-CBP-HA (Luo et al.,
2004). The protein-DNA binding reactions (20 ml) contained 20 mM HEPES
(pH 7.6), 80mMNaCl, 0.1mMEDTA, 12.5%glycerol, 2mMMgCl2, 2mMsper-
midine, 0.7 mM DTT, 200 ng/ml BSA, 20 ng/ml sheared sperm DNA, 10–20 fmol
DNA probe, 20 ng Flag-p53, Flag-p53-8KR, or acetylated Flag-p53. InCell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc. 621
Figure 5. Acetylation Disrupts the p53-Mediated Mdm2-p53-DNA Complex Formed In Vitro
(A) The fully acetylated Flag-p53 proteins were purified from H1299 cells cotransfected with plasmid DNA expressing CMV-Flag-p53, CMV-Tip60, and CBP-HA.
Acetylation levels were examined by western blot using site-specific acetylation antibodies, as indicated.
(B) Gel shift assay was performed, according to the Experimental Procedures, to analyze Mdm2-p53-DNA complex. A 32P-labeled 159 bp DNA fragment con-
taining the p53-binding site from the human p21 promoter was incubated with proteins, as indicated. The reaction was resolved by 4% PAGE and protein-DNA
complexes were visualized by autoradiography.
(C) Gel shift assays were carried out as in (B). The DNA probe was incubated with the Flag-p53, Flag-p53-8KR, or acetylated Flag-p53 proteins (20 ng) in the
absence or presence of an increasing amounts of GST-Mdm2.
(D) In vitro binding ofMdm2 to the various domains of p53. The in vitro translated 35S-methionine-labeledMdm2 protein was used in the pull-down assaywith GST
(lanes 5), GST-p53 (1–73) (lane 2), GST-p53 (100–290) (lane 3), or GST-p53 (290–393) (lane 4). The glutathione elutes and 15% input materials (lane 1) were re-
solved in SDS-PAGE gel and visualized by autoradiography. Levels of the recombinant proteins were shown in the Figure S6B.622 Cell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc.
supershift assays, antibodies (a-p53 [1801], 200 ng; a-Mdm2, 1 mg; a-Mdmx,
1 mg) and an increasing amount of GST-Mdm2 or GST-Mdmx (?30, 100, or
250 ng) were added to the reactions, accordingly. The 159 bp DNA fragment
used as probe was obtained by PCR amplification from the human p21 pro-
moter, labeled by T4 kinase (NEB, M0201S) and purified using the Bio-Spin
30 columns (Bio-Rad).
Figure 6. Recruitment of Mdm2 to the p21 Promoter in Response to DNA Damage
(A) Cell extracts from U2OS cells treated with actinomycin D (10 nM) for 0, 4, 8, 16, and 24 hr were fractionated in SDS-PAGE gel and analyzed by western blot
using antibodies against p53 (FL), Mdm2, ser-15-phospho-p53, and actin. Acetylation levels of p53 were determined by immunoprecipitation with site-specific
acetylation antibodies followed by western blot using a monoclonal p53 antibody DO-1.
(B) U2OS cells were treated as in (A) and processed for ChIP assay. The binding of p53 and Mdm2 to the p21 promoter was detected by PCR.
(C) The Flag-p53 proteins were immunoprecipitated with M2 beads from the total cell extracts of H1299 cells infected with the indicated adenoviruses for 24 hr
and treated with or without actinomycin D (10 nM) for 16 hr. The levels of acetylation or phosphorylation were detected by western blot using site-specific
antibodies.
(D) H1299 cells were infected and treated as in (C) and processed for ChIP assay. The binding of p53 and Mdm2 to the p21 promoter was detected by PCR.(E) In the GST-pull-down assays, the purified p53 or acetylated p53 proteins were incubated with GST (lanes 7 and 8), GST-Mdm2 (lanes 5 and 6), or GST-Mdmx
(lanes 3 and 4). The glutathione eluted material and 5% input materials (lanes 1 and 2) were analyzed by western blot using anti-p53 antibody (DO-1). GST fusion
proteins were shown in Figures S6C and S6D.Cell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc. 623
Figure 7. Cell Growth Repression Function of p53 Is Abrogated by Loss of Acetylation but Rescued by siRNA-Mediated Ablation of Mdm2
and Mdmx
(A) Tet-off-p53 cells and Tet-off-p53-8KR cells treated with control siRNA, Mdm2 siRNA, Mdmx siRNA, or a combination of Mdm2 siRNA andMdmx siRNA, were
induced by removal of tetracycline from themedia. The total cell extracts were analyzed bywestern blot using antibodies against p53 (DO-1), Mdmx,Mdm2, Pig3,
p21, and actin.
(B) In the upper panel, p53-8KR is unable to induce cell death and growth arrest. Tet-off-p53 and Tet-off-p53-8KR cells were plated at 10% confluence and in-
cubated in the presence (uninduced) or absence (induced) of tetracycline for 6 days. The plates were washed with PBS and stained with crystal violet. In the lower624 Cell 133, 612–626, May 16, 2008 ª2008 Elsevier Inc.
Chromatin Immunoprecipitation (ChIP)
ChIP assay was performed essentially according to the protocol (Aparicio
et al., 2004) with some modifications. Briefly, adherent cells were incubated
in culture media containing 1% formaldehyde with gentle shaking for 10 min
at room temperature, and crosslinking was stopped by addition of 2.5 M gly-
cine to a final concentration of 0.125 M glycine. After two washes with cold
PBS, cells were harvested in ice cold lysis buffer (10 mM Tris-Cl [pH 8.0],
85 mM KCl, 0.5% NP-40, 5 mM EDTA, and fresh proteinase inhibitor cocktail)
and incubated on ice for 10 min. Nuclei were collected, suspended in cold
RIPA buffer (10 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.1% DOC,
1%Triton X-100, 5mMEDTA, and fresh proteinase inhibitor cocktail), and son-
icated to shear the genomic DNA to an average of 300 bp. Cleared extracts
were blocked with protein A/G beads (Upstate Biotechnology), and aliquots
of the supernatants were used for immunoprecipitation by various antibodies.
After seven washes by RIPA buffer with gentle rotation for 5 min each time, the
proteins were eluted from the beads by 0.5 ml elution buffer (0.1 M NaHCO3
and 1%SDS). The DNA sampleswere recovered by phenol extraction and eth-
anol precipitation after reversal of crosslinking. The purified DNA was then an-
alyzed either by PCR within linear amplification range followed by agarose gel
electrophoresis or by quantitative real-time PCR using Applied Biosystems
7300.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and 12
figures and can be found online at http://www.cell.com/cgi/content/full/133/
4/612/DC1/.
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